The Oncology Institute, Inc. (TOI) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -70%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.22, delivering a surprise of -83.33%. Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-39248 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdictio ...

FOR IMMEDIATE RELEASE The Oncology Institute Reports Second Quarter 2024 Financial Results and Updates Full Year 2024 Guidance CERRITOS, Calif., August 13, 2024 -- The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three and six months ended June 30, 2024 and updated its full year 2024 guidance. Recent Operational Highlights Include • 76% increase in Dispensary segment re ...

The Company's quarterly results will be disseminated via press release and made available on the Company's website (www.topicus.com) and the SEDAR website (www.sedarplus.ca), after markets close on Thursday, August 1, 2024. About Topicus.com Inc. Jamal Baksh Chief Financial Officer 416-861-9677 TORONTO, July 15, 2024 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) announced today it intends to release its second quarter results on August 1, 2024. Topicus' subordinate voting shares are listed on the Toronto ...

Company Participants Operator The Oncology Institute, Inc. (NASDAQ:TOI) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Conference Call Participants Good afternoon and welcome to The Oncology Institute's First Quarter 2024 Earnings Conference Call. Today's call is being recorded. And we have allocated one hour for prepared remarks and Q&A. At this time, I would like to turn the conference over to Mihir Shah, Chief Financial Officer at TOI. Thank you. You may begin. The press release announcing The ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-39248 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdicti ...

The Oncology Institute Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Guidance FOR IMMEDIATE RELEASE CERRITOS, Calif., May 14, 2024 -- The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2024. Recent Operational Highlights Include: First Quarter 2024 Financial Highlights First Quarter 2024 Results Management Commentar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-39248 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware 84-3562323 (State or o ...

The Oncology Institute, Inc. (NASDAQ:TOI) Q4 2023 Earnings Conference Call March 27, 2024 05:00 PM ET Mark Hueppelsheuser - General Counsel Dan Virnich - Chief Executive Officer Mihir Shah - Chief Financial Officer Jack Slevin - Jefferies Good afternoon, and welcome to The Oncology Institute's Fourth Quarter 2023 and Full Year 2023 Earnings Conference Call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A. Mark Hueppelsheuser Before we get started, I would like to ...

FOR IMMEDIATE RELEASE The Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024 CERRITOS, Calif., March 27, 2024 -- The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2023. Recent Operational Highlights Fourth Quarter 2023 Financial Highlights Management Commentary Daniel Virnich, CE ...